Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) have earned an average recommendation of “Moderate Buy” from the twenty-five brokerages that are covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, six have issued a hold rating, sixteen have assigned a buy rating and two have given a strong buy rating to the company. The average twelve-month price objective among brokers that have updated their coverage on the stock in the last year is $973.13.

A number of research firms have commented on REGN. Wolfe Research began coverage on Regeneron Pharmaceuticals in a research note on Friday, November 15th. They set an “outperform” rating and a $1,150.00 price target on the stock. Robert W. Baird decreased their price target on Regeneron Pharmaceuticals from $940.00 to $759.00 and set a “neutral” rating on the stock in a research note on Wednesday, February 5th. UBS Group cut Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and decreased their price target for the stock from $1,130.00 to $738.00 in a research note on Thursday, January 16th. Bank of America restated an “underperform” rating and set a $565.00 price target on shares of Regeneron Pharmaceuticals in a research note on Tuesday, December 10th. Finally, Canaccord Genuity Group cut Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, December 17th.

Hedge Funds Weigh In On Regeneron Pharmaceuticals

Hedge funds have recently made changes to their positions in the company. Rakuten Securities Inc. grew its holdings in shares of Regeneron Pharmaceuticals by 380.0% during the third quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 19 shares during the last quarter. Pinney & Scofield Inc. purchased a new position in shares of Regeneron Pharmaceuticals during the fourth quarter worth about $25,000. FSA Wealth Management LLC purchased a new position in shares of Regeneron Pharmaceuticals during the third quarter worth about $26,000. OFI Invest Asset Management purchased a new position in shares of Regeneron Pharmaceuticals during the fourth quarter worth about $28,000. Finally, Avalon Trust Co purchased a new position in shares of Regeneron Pharmaceuticals during the fourth quarter worth about $36,000. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Trading Down 2.0 %

Shares of Regeneron Pharmaceuticals stock opened at $684.87 on Tuesday. The firm has a market capitalization of $74.87 billion, a price-to-earnings ratio of 17.89, a PEG ratio of 2.34 and a beta of 0.08. Regeneron Pharmaceuticals has a fifty-two week low of $642.00 and a fifty-two week high of $1,211.20. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.95 and a current ratio of 4.73. The stock has a 50 day moving average of $697.91 and a 200 day moving average of $862.68.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share for the quarter, topping the consensus estimate of $11.21 by $0.86. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The company had revenue of $3.79 billion during the quarter, compared to analyst estimates of $3.76 billion. During the same period in the prior year, the business posted $11.86 earnings per share. The firm’s revenue for the quarter was up 10.3% compared to the same quarter last year. As a group, research analysts predict that Regeneron Pharmaceuticals will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, March 20th. Shareholders of record on Thursday, February 20th will be issued a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a dividend yield of 0.51%. The ex-dividend date of this dividend is Thursday, February 20th. Regeneron Pharmaceuticals’s payout ratio is 2.30%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.